Azitra (AZTR) Asset Writedowns and Impairment (2026)
Azitra (AZTR) posted Asset Writedowns and Impairment of $623532.0 for Q1 2026.
Azitra (AZTR) Asset Writedowns and Impairment (2026) Analysis & Trends
Azitra's Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $623532.0 for Q1 2026.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $623532.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $623532.0 (changed N/A YoY) and the FY2024 annual result came in at $442793.0, up 26.02% from the prior year.
- Asset Writedowns and Impairment was $623532.0 for Q1 2026 at Azitra.
- Across five years, Asset Writedowns and Impairment topped out at $623532.0 in Q1 2026 and bottomed at $623532.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Nanobiotix | 1,769.80 Bn | 1,769.74 Bn | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 3 | BeOne Medicines | 473.64 Bn | 468.85 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 123.74 Bn | 116.49 Bn | 2.59 Bn |
| 5 | Regeneron Pharmaceuticals | 71.73 Bn | 62.97 Bn | 3.31 Bn |
| 6 | Belite Bio | 62.10 Bn | 62.10 Bn | - |
| 7 | Argenx Se | 54.68 Bn | 49.49 Bn | 1.41 Bn |
| 8 | Alnylam Pharmaceuticals | 38.13 Bn | 35.12 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 36.21 Bn | 36.21 Bn | - |
| 10 | Azitra | 2.03 Mn | 2.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 623,532.00 |
| Mar 31, 2026 | 623,532.00 |